Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02388295 · ClinicalTrials.gov registry record · Phase 2
AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
A Phase 2 study of Multiple System Atrophy (MSA), sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 17
- Study locations
NCT02388295 is a Phase 2 study of Multiple System Atrophy (MSA) that has completed, run by AstraZeneca. The registered enrollment target is 59 participants. The trial reports 17 study locations across 8 states.
The verdict
NCT02388295, a Phase 2 study of Multiple System Atrophy (MSA), has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 17
- Study locations
Study Summary
AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD3241
Study Locations (17)
Other
- Research Site - Innsbruck
- Research Site - Turku
- Research Site - Bordeaux
- Research Site - Toulouse
- Research Site - Salerno
- Research Site - Stockholm
- Research Site - London
- Research Site - London
- Research Site - Oxford
New York
- Research Site - New York
- Research Site - New York
California
- Research Site - Stanford
Connecticut
- Research Site - New Haven
Florida
- Research Site - Tampa
Massachusetts
- Research Site - Boston
Michigan
- Research Site - Ann Arbor
Minnesota
- Research Site - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2015-04-27 |
| Est. Completion | 2016-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02388295
The ClinicalTrials.gov registry entry for NCT02388295 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple System Atrophy (MSA) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02388295 reports 17 study locations spanning 8 distinct geographic areas - top geographies include Other, New York, California.
Frequently Asked Questions
What is clinical trial NCT02388295 about?
NCT02388295 is a clinical study titled "AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients". AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.
What is the current status of trial NCT02388295?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2015-04-27. Estimated completion is 2016-09-19.
What conditions does trial NCT02388295 study?
This clinical trial studies the following conditions: Multiple System Atrophy (MSA).
What interventions are being tested in trial NCT02388295?
The interventions under investigation include: Placebo (DRUG), AZD3241 (DRUG).
Who is sponsoring clinical trial NCT02388295?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02388295 being conducted?
This trial has 17 study locations across California, Connecticut, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple System Atrophy (MSA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.